1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Saalfeld, F.C., Möller, J., Michels, S., Grohe, C., Wiesweg, M., Schubart, C., Alt, J., Griesinger, F., Kauffmann-Guerrero, D., Kulhavy, J., Overbeck, T.R., Pelusi, N., Rohde, G., Wesseler, C., Vathiotis, I., Veluswamy, R., Illini, O.M., Rothschild, S.I., Christopoulos, P., Wermke, M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients
Hochmair, M.J., Weinlinger, C., Fabikan, H., Koger, R., Krenbeck, D., Huemer, F., Illini, O.M., Kulaksiz, M., Valipour, A., Burghuber, O.C.
Published in Annals of oncology (01.04.2019)
Published in Annals of oncology (01.04.2019)
Get full text
Journal Article